We won’t stop now!

PanCAN-BMS SCIENTIFIC SESSION WITH GRANTEES
WEDNESDAY, SEPTEMBER 16, 2020

Through PanCAN’s partnership with Bristol Myers Squibb (formerly Celgene), PanCAN’s Translational Research Grants have been awarded to 16 researchers across 10 different institutions for a total of $8 million. This partnership is pushing high-priority pancreatic cancer research projects toward translational next steps, moving scientific discovery to application in patients.


We're looking forward to coming together to discuss these projects and outcomes, next steps and opportunities for further collaboration.


Bristol Myers Squibb’s support has been essential for our research community. PanCAN and our research grant recipients thank you for the instrumental role you play in advancing science and bringing new treatment options to patients!


To make the most of our time during the Joint Steering Committee Meeting on Sept. 16, watch the 15-minute presentations at the links below in advance of the meeting.
Please come prepared with questions and topics for discussion with the group.


These presentations are shared in confidence and in good faith. Please do not share the link or any information viewed within, unless you request and receive explicit written approval from the content creator.

Activating the Immune System

presenter image

Immunotherapy for Pancreatic Cancer Saposin C-based Nanovesicles

Xiaoyang Qi, PhD

2020 Grantee

University of Cincinnati

presenter image

Activating Anti-Tumor Immunity by Targeting A Ubl Modification

Yuan Chen, PhD

2019 Grantee

University of California, San Diego

presenter image

Pro-Inflammatory Conversion of the PDAC Microenvironment

Michael Curran, PhD

2018 Grantee

MD Anderson Cancer Center

Disrupting Critical Metabolic Pathways

presenter image

Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer

Kenneth Olive, PhD

2020 Grantee

Columbia University Medical Center

presenter image

Exploiting a Metabolic Vulnerability Created by Epigenetic Therapy

Susan Bates, MD

2020 Grantee

Columbia University Medical Center

presenter image

Targeting Syndecan1 in Pancreatic Cancer

Wantong Yao, MD, PhD

2019 Grantee

MD Anderson Cancer Center

presenter image

Pre-Clinical Development of a ULK1/2 Inhibitor for Pancreatic Cancer

Nicholas Cosford, PhD

2019 Grantee

Sanford Burnham Prebys Medical Discovery Institute

presenter image

ATG4 Family Members as Therapeutic Targets for Pancreatic Cancer

Sharon Gorski, PhD

2018 Grantee

British Columbia Cancer Agency Branch (BC Cancer)
Co-PI: Robert Young, MC, FRSC
Simon Fraser University

Targeting Signaling and Repair Pathways

presenter image

Validation of Targets as Biomarkers for Targeted Pancreatic Cancer Therapy

Fengzhi Li, PhD

2020 Grantee

Roswell Park Comprehensive Cancer Center

presenter image

Targeting dePARylation for Pancreatic Cancer Treatment

Yilun Liu, PhD

2019 Grantee

Beckman Research Institute of the City of Hope

presenter image

A Novel Super-Enhancer Associated Target in Pancreatic Cancer

Andrew Lowy, MD, FACS

2019 Grantee

University of California, San Diego

presenter image

Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer

Darren Carpizo, MD, PhD

2018 Grantee

University of Rochester Medical Center
Co-PI: Patrick Mehlen, PhD
Research Cancer Center of Lyon (CRCL)

presenter image

Keratin 17 is a Novel Actionable Target in Pancreatic Ductal ADENOCARCINOMA

Kenneth Shroyer, MD, PhD

2018 Grantee

Stony Brook University
Co-PI: Luisa Escobar-Hoyos, PhD, MSC
Yale School of Medicine

SEPTEMBER 16, 2020 | 9 a.m. – 1:30 p.m. Pacific / Noon – 4:30 p.m. Eastern

9 – 9:15 A.M.

INTRODUCTIONS/WELCOME

Julie Fleshman, JD, MBA, President and CEO, PanCAN
Lynn Matrisian, PhD, MBA, Chief Science Officer, PanCAN
Susanna Parathath, PhD, Business Development and Global Alliances, BMS
Daniel Pierce, PhD, Executive Director, BMS
Thomas Lila, PhD, Associate Director, BMS
Peter Strack, PhD, Research Alliance Group, BMS

9:15 – 9:35 A.M.

WHAT MAKES A TRANSLATIONAL PROJECT GOOD? A PHARMA PERSPECTIVE

Daniel Pierce, PhD, Executive Director, Translational Medicine, BMS

9:35 – 9:40 A.M.

BREAK

9:40 – 10:25 A.M.

ACTIVATING THE IMMUNE SYSTEM

9:40 – 9:55 A.M.

Xiaoyang Qi, PhD, 2020 Grantee

University of Cincinnati

Immunotherapy for Pancreatic Cancer Saposin C-based Nanovesicles

9:55 – 10:10 A.M.

Yuan Chen, PhD, 2019 Grantee

University of California, San Diego

Activating Anti-Tumor Immunity by Targeting a Ubl Modification

10:10 – 10:25 A.M.

Michael Curran, PhD, 2018 Grantee

MD Anderson Cancer Center

Pro-Inflammatory Conversion of the PDAC Microenvironment

10:25 – 10:30 A.M.

BREAK

10:30 – 11:50 A.M.

DISRUPTING CRITICAL METABOLIC PATHWAYS

10:30 – 10:45 A.M.

Kenneth Olive, PhD, 2020 Grantee

Columbia University Medical Center

Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer

10:45 – 11 A.M.

Susan Bates, MD, 2020 Grantee

Columbia University Medical Center

Exploiting a Metabolic Vulnerability Created by Epigenetic Therapy

11 – 11:15 A.M.

Wantong Yao, MD, PhD, 2019 Grantee

MD Anderson Cancer Center

Targeting Syndecan1 in Pancreatic Cancer

11:15 – 11:20 A.M.

Break

11:20 –11:35 A.M.

Nicholas Cosford, PhD, 2019 Grantee

Sanford Burnham Prebys Medical Discovery Institute

Pre-Clinical Development of a ULK1/2 Inhibitor for Pancreatic Cancer

11:35 – 11:50 A.M.

Sharon Gorski, PhD, 2018 Grantee

British Columbia Cancer Agency Branch (BC Cancer)

ATG4 Family Members as Therapeutic Targets for Pancreatic Cancer

11:50 A.M. – 12:10 P.M.

Break

12:10 – 1:30 P.M.

TARGETING SIGNALING AND REPAIR PATHWAYS

12:10 – 12:25 P.M.

Fengzhi Li, PhD, 2020 Grantee

Roswell Park Comprehensive Cancer Center

Validation of Targets as Biomarkers for Targeted Pancreatic Cancer Therapy

12:25 – 12:40 P.M.

Yilun Liu, PhD, 2019 Grantee

Beckman Research Institute of the City of Hope

Targeting dePARylation for Pancreatic Cancer Treatment

12:40 – 12:55 P.M.

Andrew Lowy, MD, FACS, 2019 Grantee

University of California, San Diego

MICAL2: A Novel Super-Enhancer Associated Target in Pancreatic Cancer

12:55 – 1 P.M.

Break

1 – 1:15 P.M.

Darren Carpizo, MD, PhD, 2018 Grantee

University of Rochester

Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer

1:15 – 1:30 P.M.

Kenneth Shroyer, MD, PhD, 2018 Grantee

Stony Brook University

Keratin 17 is a Novel Actionable Target in Pancreatic Ductal Adenocarcinoma

1:30 P.M.

ADJOURN

Lynn Matrisian

Follow us

Wage Hope With Us

Join us to make a difference for pancreatic cancer patients.





shop purple logo

Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2020 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.